China completes 2026 drug reimbursement list negotiations

The conclusion of negotiations is a pivotal step for drug pricing and access in China's vast state-run healthcare market. The focus on innovative drugs for high-need areas like oncology and rare diseases signals a continued policy push to reward R&D, but inclusion hinges on the delicate balance of pricing concessions. This directly affects global pharma and biotech firms seeking market entry, as well as domestic innovators. The key watchpoint is the November release—specifically, which drugs made the cut and at what price, as that will set the tone for future pricing benchmarks and market access strategies.